Emergent BioSolutions Appoints Barry Labinger as Executive Vice President of the Company and President of Its Biosciences Division
Emergent BioSolutions Inc. (NYSE:EBS) announced today that Barry Labinger has been named Executive Vice President and President, Biosciences Division, reporting directly to Daniel J. Abdun-Nabi,...
Emergent BioSolutions Reports Financial Results for Second Quarter and First Six Months of 2013
Emergent BioSolutions Inc. (NYSE: EBS) announced today its financial results for the second quarter and six months ended June 30,...
Emergent BioSolutions Closes on Its Acquisition of Healthcare Protective Products Division from Bracco Diagnostics Inc.
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has closed on its acquisition of Bracco Diagnostics Inc.’s Healthcare Protective Products Division....
Emergent BioSolutions to Webcast Presentation at Wedbush 2013 Life Sciences Management Access Conference
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Wedbush 2013 Life Sciences Management Access Conference in New York on August 14,...
General George A. Joulwan Joins Emergent BioSolutions Board of Directors
Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of General George A. Joulwan (retired) to the company’s Board of...
Emergent BioSolutions Advances Program Supporting Licensure of a Post-Exposure Prophylaxis Indication for BioThrax
Emergent BioSolutions Inc. (NYSE: EBS) today announced that its pivotal Phase 3 clinical study evaluating the immunogenicity and safety of a three-dose BioThrax® (Anthrax Vaccine Adsorbed) regimen...
Emergent BioSolutions to Release Second Quarter 2013 Financial Results and Conduct a Conference Call on August 5, 2013
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it will report financial results for the second quarter 2013 on Monday, August 5, 2013, after market...
Emergent BioSolutions Receives Paul-Ehrlich-Institut Approval to Market BioThrax in Germany
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Paul-Ehrlich-Institut (PEI) has approved Emergent’s marketing authorization application for BioThrax® (Anthrax Vaccine Adsorbed) in...
Emergent BioSolutions EVP Corporate Affairs Allen Shofe Appointed to MdBio Foundation Board of Directors
Emergent BioSolutions Inc. (NYSE:EBS) announced today that Allen Shofe, executive vice president of corporate affairs, has been appointed to serve on the board of directors of the MdBio Foundation, a...
Mayor Virg Bernero Leads Ribbon Cutting of Emergent BioSolutions’ New Administration Building Representing Another Step in Its Lansing Campus Expansion
Lansing, Michigan Mayor Virg Bernero and senior executives from Emergent BioSolutions Inc. (NYSE:EBS) today held a ribbon cutting ceremony to commemorate the formal opening of a new administration...
Emergent BioSolutions to Participate in June and July 2013 Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during June and July...
Emergent BioSolutions to Webcast Presentation at Jefferies 2013 Global Healthcare Conference
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Jefferies 2013 Global Healthcare Conference in New York on June 3, 2013 at 9:00 AM...